Medical Oncology Department

IRCCS San Raffaele Hospital

Neoplasm Metastasis

Endocrine Gland Cancer

Lymphatic Metastasis

Prolapse

Pancreatic Cancer

Abdominal Aortic Aneurysm

Aortic Aneurysm

Carcinoma

Eosinophilic Esophagitis

Cancer

Crenolanib

San Donato Group (GSD)

Maastricht University

Arog Pharmaceuticals

Cook Group

Istituto Clinico Humanitas

Paolo Giorgio Arcidiacono, MD

condition

Acute Myeloid Leukemia

Leukemia

Myeloid Leukemia

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This is a randomized, multi-center, double-blind, placebo-controlled study designed to evaluate the efficacy of crenolanib administered following salvage chemotherapy, consolidation chemotherapy, post bone marrow transplantation and as maintenance in relapsed/refractory AML subjects with FLT3 activating mutation.

Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

IRCCS San Raffaele Hospital | Medical Oncology Department

Site insights

Work at this site?

Active trials

Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

Trial sponsors